CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Sponsor: Daiichi Sankyo
A PHASE2 clinical study on Advanced Hepatocellular Carcinoma and Hepatic Cancer, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 11 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
May 2021 — Mar 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Changhua, Taiwan , Chiayi City, Taiwan , Chiba, Japan , Daegu, South Korea , Hiroshima, Japan , Kanazawa, Japan , Kaohsiung City, Taiwan , Kurume-shi, Japan , Los Angeles, United States , Nashville, United States and 10 more locations